Integra Lifesciences Holdings (IART) Free Cash Flow (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Free Cash Flow data on file, last reported at -$5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 87.44% year-over-year to -$5.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (up 126.32% YoY), and the FY2025 full-year result was -$31.1 million, down 224.39% from the prior year.
• Free Cash Flow climbed to -$5.0 million in Q1 2026, from -$5.4 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $70.9 million in Q4 2022 to a low of -$40.2 million in Q1 2025.
• A 5-year average of $16.7 million and a median of $12.7 million in 2023 frame the typical range for Free Cash Flow.
• Peak annual rise in Free Cash Flow reached 459.59% in 2025, while the deepest fall reached 13906.53% in 2025.
• Tracing IART's Free Cash Flow over 5 years: stood at $70.9 million in 2022, then slumped by 51.73% to $34.2 million in 2023, then plunged by 38.21% to $21.1 million in 2024, then slumped by 125.53% to -$5.4 million in 2025, then increased by 6.54% to -$5.0 million in 2026.
• Business Quant data shows IART's Free Cash Flow at -$5.0 million in Q1 2026, -$5.4 million in Q4 2025, and $25.8 million in Q3 2025.